Using VE-statins to inhibit recruitment of perivascular smooth muscle cells, for treating e.g. cancer and retinopathy, also new VE-statins, related nucleic acids and antibodies

摘要

Use of a protein designated VE-statin (I) in preparation of a composition for inhibiting recruitment of perivascular cells of smooth muscle type. Use of a protein designated VE-statin (I) in preparation of a composition for inhibiting recruitment of perivascular cells of smooth muscle type. (I) is (a) a 275 amino acid (aa) sequence (1), murine VE-statin; (b) sequences with at least 70, best 95, % identity or at least 85, best 99, % similarity with (1); (c) the n-275 regions of (1), where n = 17-24; (d) a 255 aa sequence (2) or 254 aa sequence (3), the mature forms of murine and human VE-statins; (e) a 273 aa sequence (42), NCBI NP-057299, human VE-statin; and (f) the m-273 regions of (42), where m = 16-23. Independent claims are also included for: (1) isolated, purified VE-statins of sequence (a) or of item (b) above, excluding those with accession numbers AAF01322, NP-057299, BAB22222 and AAH12377; (2) a peptide fragment (II) of item (1) containing at least 7 aa; (3) isolated nucleic acid (III) that encodes proteins of (1) or is a 1539 bp sequence (d), encoding human VE-statin, also their complements, sense or antisense; (4) primers and probes that are fragments of at least 8 bp of (III), excluding the expressed sequence tag BI910383 and the cDNA fragment NM-016215; (5) recombinant vector that includes (III) or the fragments of (4) as an insert; (6) cells transformed with the vector of (5); (7) antibody (Ab) directed against the proteins of (1) or peptides of (2); (8) transgenic non-human animals containing cells transformed by (II); and (9) method of screening for agonists or antagonists of the proteins of (A). ACTIVITY : Cytostatic; Ophthalmological; Vasotropic; Antiarteriosclerotic. No details of tests for these activities are given. MECHANISM OF ACTION : VE-statins, soluble factors secreted by endothelial cells of the blood vessels, block recruitment of perivascular smooth muscle cells (but do not affect their proliferation), so inhibit angiogenesis.